18
APSC WHF ESC ESC (1) (2) 1. 2010 Post ACC Highlight 99 5 8 2. 99 5 22-23 5/22 W6 / TSOC joint session (3) 19 99 5
ICD/CRT registry focus heart failure 5/22 w6 clinical skill on heart failure join Joseph C. Wu ABC publish on-line, hand-on ACS registry open submit committee data publish 3/31 publish data 20
( ) 1. () 2. 1) / 99.5.22 w6 08:30-12:00AM TICC, Room 105 oral poster 2) / 99.5.22(w6) 13:30-17:00PM TICC, Room 105 EP 3) 90 25 15 21 99 5
4) w5-w1or2 w5-w7, w6-7 5) 6) ( ) 1. Euro Score Euro Score previous PCI 2. Aortic Valve Implantation 1) Aortic Regurgitation Aortic stenosis 2) 3. ( ) 1. 1) 2) 22
3) No. 1 2 3 4 5 6 7 8 9 10 11 04) 05) 11 06) 07) 08) 09) 10) 11) 23 99 5
( ) 1. 24 2. 1) 3~4 Speakers 6 Speaker 3 2) slides 3) Topic Speaker ( ) 1. ICD/ CRT ICD/ CRT 99 3 2. St. Jude-sponsored Cross-strait Pacemaker Meeting 1) 99.08.07 w6 2) case presentation and discussion 30 10 3) / /Moderator Session 1: Topic Speaker Moderator AV optimization: How to optimize AV/PV, how long is too long? How to distinguish pacemaker malfunction & Pseudo malfunctions Diagnostic valve of stored EGM Session 2: Topic Speaker Moderator RVOT pacing experience sharing Atrial Septal Pacing 24
( ) 1. 1) Invatec Amphirion Deep PTA balloon catheter 1. a) 70% b) - Fontaine Stage IIb / - Fontaine Stage III / - Fontaine Stage IV 2) Invatec CHROMIS Deep Peripheral Stent System 1. 1) 70% 2) - Fontaine Stage IIb / - Fontaine Stage III / - Fontaine Stage IV 2. 25 99 5
1) 40% 2) 35 mm 2. live demo demo general, up to day advanced ( ) 1. AMI AMI_STEMI 2. ACLS ACLS 3. ACLS ACLS ACLS ACLS ACLS 4. Heart Sunsim Reader 26
( ) 1. 1. 5-7 2. 3. 4. 1/3 (1) Present-elect (2) (3) 2. ( ) 1. 27 99 5
NO. 1 98.07.01-100.06.30 2 98.07.01-101.06.30 3 98.08-100.07 4 98.07.01-98 11 23 5 98.09.11-99 3 2 2. 97.8.5-10.6 1) 97.11.04 97 10 20 99.10.19 2) 97.08.05-97.10.06 3) 97 2 0 3. S1166 98 11 24 28
4. N1119 99.02.25 5. 1) 11 99 99 100 2) 99 99 100 6. X 7. 91-98 ( ) 1. APSC-ESC Heart Failure Pilot Registry IRB APSC ESC ID password 29 99 5
IRB ( ) 99.5.22-23/ 1. 239 112 oral 127 poster Oral Poster 1 Electrophysiology 13 15 2 Cardiac Imaging-ECHO, MRI, CT, NUCLEAR, PET 9 19 3 Hypertension 5 6 4 Pediatric Cardiology 7 0 5 Cardiovascular Surgery 10 1 6 Coronary Artery Disease- Intervention, Drug treatment 22 24 7 Basic Science 24 28 8 Heart Failure 6 7 9 General Cardiology- Valvular disease, Epidemiology, etc... 16 27 112 127 1) 5/22 w6 08:30-10:00am TICC South Foyer 3F * * EP CAD Basic General Surgery Imaging, Hypertension, Heart Failure 15 30
990108 990603 990715 990909 990505 990302 2) Oral presentation Pediatric Cardiology 7 Oral poster Hypertension & Heart Failure - / 3+3 990303 990305 990304 990802 990804 990806 Cardiac Imaging - / 6 990203 990201 990207 990205 990202 990204 Basic Science (I) - / 6 990716 990718 990701 990703 990704 990712 Basic Science (II) - / 4 991731 990723 990709 990717 Electrophysiology - / 6 990113 990107 990106 990101 990111 990104 General Cardiology (I) - / 6 990912 990908 990910 990901 990911 990913 General Cardiology (II) - / 6 990904 990916 990907 990905 990906 990915 31 99 5
Cardiovascular Surgery- / 6 990508 990510 990511 990504 990509 990502 Coronary Artery Disease- / 12 990609 990611 990615 990606 990605 990608 / 990601 990622 990610 990604 11 990614 12 990621 3) 5/22 w6 08:30-12:3 0am TICC 1F, 2F Basic EP Hypertension, Heart Failure, Pediatric, Surgery Basic 991707 991712 991719 991708 991703 EP 991104 991105 991103 991107 991111 Hypertension, Heart Failure, Pediatric, Surgery 991305 991303 990401 990407 991807 32
5/22 w6 13:30-17:30pm TICC 1F, 2F General Imaging CAD General 991902 991919 991925 991922 991921 Imaging 991212 991213 991204 991215 991205 CAD 991605 991617 991618 991608 991615 2. 99.05.22 w6 10:30-12:00AM TICC South Foyer 3F * * Intramuscular Transplantation of Amniotic 10:30-10:45 Fluid-derived Stem Cells Improves Postnatal Angiogenesis in a Mouse Model of Hindlimb Ischemia Heart Failure Enhanced Fibrillatory Activities in 10:45-11:00 Small Pulmonary Vein and Left Atrium Tissue: Potential Mechanisms of Atrial Fibrillation 11:00-11:15 Molecular Characterization of Thyroid Hormone-inhibited Atrial L-type Calcium Channel Expression: Implication for Atrial Fibrillation in Hyperthyroidism 33 99 5
Reversal of Vascular Inflammation by 11:15-11:30 12-Week Atorvastatin Treatment: A prospective 18 F-FDG PET/CT Imaging Study The Impact of Age on the Electroanatomical 11:30-11:45 Characteristics and Outcome of Catheter Ablation in Patients with Atrial Fibrillation 11:45-12:00 Non-carriers of Reduced-function CYP2C19 Alleles are Most Susceptible to the Impairment of the Anti-Platelet Effect of Clopidogrel by Concomitant Use of Proton-pump Inhibitor 3. 2 2 1 2 2 2 1 1 X 1 1.6 1 1 2 1 1 1 2 2 X 2 1.5 5/23 w7 08:15-08:35 & 1) 50 2) 34
3C 3) ( ) 1. 99 Clinical Application of Cardiovascular Image 99 5 22 08:30-10:10AM Room 201BC Time Topic Speaker Moderators: Intensive Lipid Lowering 08:30-08:55 Therapy Aiming Plaque Hiroyuki Daida, M.D. Regression and Stabilization 08:55-09:20 Carotid Artery Image and Dignostic TIA Clinical Application for 3-D 09:20-09:45 Image in the Diagnosis of Congenital Heart Disease Easy Application of Tissue 09:45-10:10 Doppler Imaging in Clinical Setting ( ) 98 35 99 5
( ) 1. 2010 Clinical Basic NO. Basic TW_15 TW_19 Intramuscular Transplantation of amniotic fluid-derived stem cells improves angiogenesis in a mouse model of hindlimb ischemia Atherosclerosis Modulates the Electrophysiological Effects of a Peroxisome Proliferator-Activated Receptor-Gamma Activator on Pulmonary Veins Clinical TW_05 TW_09 Downregulation of Heat Shock Protein 27 and Perpetuation of Atrial Fibrillation Non-carriers of Reduced-function CYP2C19 Alleles are the Most Susceptible to the Impairment of the Anti-Platelet Effect of Clopidogrel by Concomitant Use of Proton-pump Inhibitor 2. ACC ( ) ESC AHA NT.10,000.- invited speaker moderator 3. 99 36
( ) 99 No. 1 2 3 4 5 6 7 8 9 10 11 12 37 99 5
/ No. 1 2 3 25 4 5 6 7 ( ) 99.04.01 1) 2) 38
3) 2 1 4) 5) 100 20% 6) 7) 1) 2) 99 3) 4) 39 99 5
( ) 13 12 No. 1 4 3 2 3 4 5 6 7 8 9 10 11 12 13 40
41 1 98.08.12 2 98.08.31 3 98.09.01 4 98.09.11 5 98.09.10 6 98.09.24 7 98.12.24 8 99.01.06 9 99.01.07 10 99.01.11 11 99.01.12 12 99.01.12 13 99.01.14 14 99.01.14 15 99.01.14 16 99.01.15 17 99.01.19 18 99.01.20 19 99.01.20 20 99.01.23 21 99.01.26 22 99.01.27 23 99.01.28 24 99.02.01 25 99.02.05 41 99 5
26 99.02.22 27 99.03.16 28 99.03.04 29 99.03.11 30 99.03.19 31 99.03.25 32 99.04.01 33 99.04.01 34 99.04.02 35 99.04.02 36 99.04.06 37 99.04.06 38 99.04.19 39 99.04.19 40 99.04.19 41 99.04.20 (1) S1083 93.12.09 / 93.07.01-95.07.10/ 99.03. (2) S1312 97.11.06 42
/ 9708.1-98.07.31/ 99.03.27 (3) S1294 97.11.06 / 98.01.01-98.12.26/ 99.04.15 ( ) 98 99 (1) 98 $42,273,222.- $39,044,350.- $3,228,872.- SCIE (2) 98 $77,527,792.- $37,640,916.- $39,886,876.- 97 $5,458,927.- (3) 98 5% NT$2,113,661.- (4) 98 $77,541,133.- 98 $20,577,808.- 5% 98 99 43 99 5
( ) N0043 S0015 (1) 99 70 9 No. 1 N0243 2 S0031 3 S0033 4 S0059 5 S0112 6 S0125 7 S0133 8 S0223 9 S0368 (2) 11 99.5.23 No. 1 N0038 3 $3,600.- 2 N0055 4 $4,800.- 3 N0452 4 $4,800.- 4 N0698 5 $6,000.- 5 N0867 5 $6,000.- 6 N0890 3 $3,600.- 7 S0062 5 $6,000.- 8 S0221 5 $6,000.- 9 S0234 5 $6,000.- 10 S0282 3 $3,600.- 11 S0716 6 $7,200.- 44
(3) 12 NO. 1 N0006 2 N0043 3 N0056 4 N0594 5 N1119 6 S0015 7 S0077 8 S0107 9 S0190 10 S0208 11 S0611 12 S0912 ( ) (1) NT$15,000.-/ 20 20 NT$15,000.-/ 20 21 NT$15,000.-/ X8 (2) 4/22 W4 4/22 W4 21 NT.12,000.- 99.04.23 ( ) CRT / 45 99 5
( ) ( ) 35% QRS 120 ( ) 35% QRS 120 ( ) 35% ( ) ( ) 35% QRS 120 ( ) 35% QRS 120 ( ) 35% ( ) 1).(1) (2) 46
(3).(1) (2) (3) 2) A. 21 3 B. comment 25 1 comment ( ) / NT. 5000.- NT.5000.- ( ) WHF WHF 1/2 1/4 1) 2) WHF 47 99 5
WHF 1/4 1/4 8 7 WHF 1/4 1/4, 1/2 ( ) 68 31 99.04.30 48
( ) 1491 41 1532 1532 11 12 / / 1 _ 1 _ 1507 1507 1. 2. 18005B 100 3. guilde LDL<100 LDL <70~80 LDL<100 guideline ( statin 80 ) LDL LDL<70 80 4. DRG IABP 49 99 5
IABP IABP DRG IABP DRG 50